구조모아 (StructureMoa)항암 chemical structure spider web
방문Sumitomo Pharma Switzerland GmbH
rabbit anti-thymocyte globulin (ATG)(Sumitomo Pharma Switzerland GmbH)은 Chronic Myeloproliferative Disorders 표적 치료제로, Chronic Myeloproliferative Disorders; Leukemia 영역에서 개발·상용화 중입니다. 작용기전: targeting RCC-associated minor histocompatibility antigen. Phase 2에서 효능·안전성 신호를 검증 중입니다. OS: 49. 차별점: novel kidney-brain axis in PD pathogenesis and proposes PKC-targeted interventions, including ATG, as potential strategies fo.
공개된 구조화 근거가 제한적입니다.
구조화 데이터
Chronic Myeloproliferative Disorders
Chronic Myeloproliferative Disorders; Leukemia
Active
2026-09-02
Data Confidence · Low
Development Signal · Emerging
Oncolytic Virus
humanized mouse models of B cell aplasia, and haematological and solid malignancies
novel kidney-brain axis in PD pathogenesis and proposes PKC-targeted interventions, including ATG, as potential strategies fo
targeting RCC-associated minor histocompatibility antigen
Cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome was the reason for ICU admission
microtubule associated protein 1 light chain 3; Mdivi-1: mitochondrial division inhibitor-1; MLD₅₀: 50% mouse lethal
biomarkers
bypassing exogenous protein regulators, while its split-ATG architecture ensures the expression of native, tag-free proteins
구조화 데이터
xenograft model
rabbit
pharmacokinetic
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Sumitomo Pharma Switzerland GmbH
rabbit anti-thymocyte globulin (ATG)(Sumitomo Pharma Switzerland GmbH)은 Chronic Myeloproliferative Disorders 표적 치료제로, Chronic Myeloproliferative Disorders; Leukemia 영역에서 개발·상용화 중입니다. 작용기전: targeting RCC-associated minor histocompatibility antigen. Phase 2에서 효능·안전성 신호를 검증 중입니다. OS: 49. 차별점: novel kidney-brain axis in PD pathogenesis and proposes PKC-targeted interventions, including ATG, as potential strategies fo.
공개된 구조화 근거가 제한적입니다.
구조화 데이터
Chronic Myeloproliferative Disorders
Chronic Myeloproliferative Disorders; Leukemia
Active
2026-09-02
Data Confidence · Low
Development Signal · Emerging
Oncolytic Virus
humanized mouse models of B cell aplasia, and haematological and solid malignancies
novel kidney-brain axis in PD pathogenesis and proposes PKC-targeted interventions, including ATG, as potential strategies fo
targeting RCC-associated minor histocompatibility antigen
Cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome was the reason for ICU admission
microtubule associated protein 1 light chain 3; Mdivi-1: mitochondrial division inhibitor-1; MLD₅₀: 50% mouse lethal
biomarkers
bypassing exogenous protein regulators, while its split-ATG architecture ensures the expression of native, tag-free proteins
구조화 데이터
xenograft model
rabbit
pharmacokinetic
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.